Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced management changes to its executive leadership team.
Mr. Allan Oberman, Senior Vice President of North America Generic Pharmaceuticals of Teva, has been appointed President and Chief Executive Officer of Teva Americas Generics as part of an orderly management succession. In his new role, Mr. Oberman will report directly to Dr. Jeremy Levin, President and Chief Executive Officer of Teva, and have continued responsibility for North America Generics as well as overall management of Teva’s Latin American businesses.
The Company also announced the appointment of Ms. Jill DeSimone to the newly created position of Senior Vice President and General Manager of Teva Global Women’s Health, overseeing all aspects of Teva's Women's Health franchise.
“These changes are part of our ongoing process to build a premier leadership team and reshape Teva,” stated Dr. Jeremy Levin, President and CEO of Teva. “Allan brings extensive experience in global generics to the Company’s Americas teams. Jill brings a great track record and many years of experience in building franchises in specialty medicine. We look forward to her contributions in leading our Women’s Health business. These changes underlie our commitment to build, in a disciplined fashion, a world class business and provide much needed medicines to patients around the world."Teva also announced today that as part of the succession, Mr. William S. Marth will step down as President and CEO of Teva Americas effective immediately and retire at the end of 2013. Mr. Marth will serve as a senior advisor to Dr. Levin until his retirement. “We greatly appreciate the contributions that Bill has made to Teva over the years, most recently leading the Teva businesses in the Americas. During this time, the Company experienced significant growth. We thank him for his tremendous service to the Company and look forward to working with him over the next year in his new capacity as a core advisor.” stated Dr. Levin.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV